Curated News
By: NewsRamp Editorial Staff
September 22, 2026
Lantern Pharma Secures Key Patent for LP-284 in Blood Cancers
TLDR
- Lantern Pharma secured a US patent for LP-284 in blood cancers, extending market exclusivity to 2042 and strengthening its competitive position.
- The USPTO issued a Notice of Allowance for Lantern Pharma's patent on LP-284, covering its use as a monotherapy and in combinations for MCL and DHL.
- Lantern Pharma's new patent for LP-284 could lead to better treatments for mantle cell lymphoma and double-hit lymphoma, improving patient outcomes.
- Lantern Pharma's AI-derived drug LP-284 received a US patent for treating rare blood cancers, with protection lasting until 2042.
Impact - Why it Matters
This patent allowance is a significant milestone for Lantern Pharma, as it strengthens the intellectual property protection for LP-284, a promising therapy for mantle cell lymphoma and double-hit lymphoma—aggressive blood cancers with limited treatment options. The extension of patent protection into 2042 provides a longer exclusivity period, potentially enhancing the drug's commercial value and attracting investment. Moreover, the method-of-use claims covering LP-284 both as a monotherapy and in combination with other anti-cancer agents could broaden its therapeutic applications and increase its market potential. For patients, this development signals progress toward new treatment options for underserved blood cancers. For investors, it underscores Lantern's commitment to advancing its pipeline and leveraging its AI platform to bring precision oncology therapies to market efficiently.
Summary
Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has received a Notice of Allowance from the USPTO for U.S. Patent Application No. 18/500,032, covering methods of using LP-284 to treat mantle cell lymphoma (MCL), double-hit lymphoma (DHL), and other blood cancers. The allowed claims encompass LP-284 as a monotherapy and in combination with several classes of anti-cancer agents. Once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern's existing composition-of-matter patent estate.
LP-284 is currently being evaluated in an ongoing Phase 1a dose-escalation clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and solid tumors. Developed through the company's RADR artificial intelligence platform, LP-284 has received three FDA Orphan Drug Designations, including for MCL, high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and soft tissue sarcomas. Lantern Pharma leverages its proprietary RADR AI and machine-learning platform to transform the cost, pace, and precision of oncology drug development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For more information, visit https://ibn.fm/5zEya.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Secures Key Patent for LP-284 in Blood Cancers
